Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

181. Direct oral anticoagulants or warfarin for A fib?

Direct oral anticoagulants or warfarin for A fib? Direct oral anticoagulants or warfarin for A fib? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Direct oral anticoagulants or warfarin for A fib? View/ Open Date 2017-08 Format Metadata Abstract A recent study evaluated the effectiveness of 3 direct oral (...) anticoagulants and warfarin in patients with atrial fibrillation. So which agents came out on top? PRACTICE CHANGER: Use direct oral anticoagulants instead of warfarin in patients with atrial fibrillation because they are just as effective at preventing ischemic stroke and systemic emboli as warfarin, and because apixaban and dabigatran have lower bleeding rates. Stength of recommendation: B: Based on a single, prospective, cohort study. URI Part of Citation Journal of Family Practice, 66(8) 2017: 518-520

2018 PURLS

182. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Full Text available with Trip Pro

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE.To compare the efficacy and safety of three types of parenteral anticoagulants (i.e. fixed-dose low molecular weight heparin (LMWH), adjusted-dose unfractionated heparin (UFH), and fondaparinux) for the initial treatment of VTE in people

2018 Cochrane

183. The survival benefits of oral anticoagulants in patients with pulmonary arterial hypertension: a meta-analysis study

The survival benefits of oral anticoagulants in patients with pulmonary arterial hypertension: a meta-analysis study Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

184. The role of anticoagulant therapy in the treatment of splanchnic venous thrombosis secondary to acute pancreatitis

The role of anticoagulant therapy in the treatment of splanchnic venous thrombosis secondary to acute pancreatitis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

185. Systematic review of the management strategies and outcomes of major or severe bleeding in patients receiving a direct oral anticoagulant (dabigatran, rivaroxaban, apixaban or edoxaban)

Systematic review of the management strategies and outcomes of major or severe bleeding in patients receiving a direct oral anticoagulant (dabigatran, rivaroxaban, apixaban or edoxaban) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2018 PROSPERO

186. The comparative efficacy and safety of anticoagulant interventions in patients with atrial fibrillation: a systematic review and network meta-analysis

The comparative efficacy and safety of anticoagulant interventions in patients with atrial fibrillation: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

187. The barriers and facilitators to continuing oral anticoagulation therapy in patients with atrial fibrillation: a systematic review protocol

The barriers and facilitators to continuing oral anticoagulation therapy in patients with atrial fibrillation: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

188. Meta-analysis and systematic review of interventional therapy vs. anticoagulation for isolated femoropopliteal DVT

Meta-analysis and systematic review of interventional therapy vs. anticoagulation for isolated femoropopliteal DVT Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

189. Non-vitamin K antagonist oral anticoagulants and cognitive impairment in atrial fibrillation: insights from a meta-analysis of over 90, 000 patients in randomized controlled trials and real-world studies

Non-vitamin K antagonist oral anticoagulants and cognitive impairment in atrial fibrillation: insights from a meta-analysis of over 90, 000 patients in randomized controlled trials and real-world studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2018 PROSPERO

190. Anticoagulation strategies for pediatric patients on ECMO support

Anticoagulation strategies for pediatric patients on ECMO support Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

191. Anticoagulant versus antiplatelet treatment in patients with cryptogenic stroke or transient ischemic attack and medically treated patent foramen ovale: systematic review and meta-analysis of randomized controlled trials

Anticoagulant versus antiplatelet treatment in patients with cryptogenic stroke or transient ischemic attack and medically treated patent foramen ovale: systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2018 PROSPERO

192. Assessment of the risk of bleeding in patients with atrial fibrillation and acute coronary syndrome treated by a direct oral anticoagulant and anti-platelets therapy: a systematic review and meta-analysis of randomized controlled trials

Assessment of the risk of bleeding in patients with atrial fibrillation and acute coronary syndrome treated by a direct oral anticoagulant and anti-platelets therapy: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration

2018 PROSPERO

193. Cost-effectiveness comparisons between direct oral anticoagulants for the prevention and treatment of venous thromboembolism

Cost-effectiveness comparisons between direct oral anticoagulants for the prevention and treatment of venous thromboembolism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

194. Coagulation effects of patients on therapeutic anticoagulation undergoing therapeutic plasma exchange

Coagulation effects of patients on therapeutic anticoagulation undergoing therapeutic plasma exchange Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

195. Real-world adherence to oral anticoagulants in atrial fibrillation patients: a systematic review

Real-world adherence to oral anticoagulants in atrial fibrillation patients: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

196. Association between oral anticoagulants and incidence of dementia/cognitive decline in patients with atrial fibrillation: a systematic review and meta-analysis

Association between oral anticoagulants and incidence of dementia/cognitive decline in patients with atrial fibrillation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

197. A systematic review of patient and healthcare practitioner perspectives on the medicines optimisation of oral anticoagulation in elderly patients (=65 years) with non valvular atrial fibrillation

A systematic review of patient and healthcare practitioner perspectives on the medicines optimisation of oral anticoagulation in elderly patients (=65 years) with non valvular atrial fibrillation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2018 PROSPERO

198. High-dose versus low(half)-dose novel oral anticoagulants for the prevention of all-cause-cause mortality in patients with coronary artery disease and/or peripheral artery disease: a systematic review and meta-analysis

High-dose versus low(half)-dose novel oral anticoagulants for the prevention of all-cause-cause mortality in patients with coronary artery disease and/or peripheral artery disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2018 PROSPERO

199. Concomitant use of antiplatelet therapy with warfarin or direct oral anticoagulants for atrial fibrillation: a systematic review and meta-analysis

Concomitant use of antiplatelet therapy with warfarin or direct oral anticoagulants for atrial fibrillation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

200. Comparative effectiveness and safety of different anticoagulant agents in patients with thromboembolic risk and chronic kidney disease: a systematic review and bayesian network meta-analysis

Comparative effectiveness and safety of different anticoagulant agents in patients with thromboembolic risk and chronic kidney disease: a systematic review and bayesian network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2018 PROSPERO